JPWO2022040128A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022040128A5 JPWO2022040128A5 JP2023511947A JP2023511947A JPWO2022040128A5 JP WO2022040128 A5 JPWO2022040128 A5 JP WO2022040128A5 JP 2023511947 A JP2023511947 A JP 2023511947A JP 2023511947 A JP2023511947 A JP 2023511947A JP WO2022040128 A5 JPWO2022040128 A5 JP WO2022040128A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sdcdr2
- sdcdr1
- sdcdr3
- sdabd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 claims description 63
- 102000037865 fusion proteins Human genes 0.000 claims description 63
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- -1 capthepsin K Proteins 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 3
- 108090000613 Cathepsin S Proteins 0.000 claims description 3
- 102100035654 Cathepsin S Human genes 0.000 claims description 3
- 102000001398 Granzyme Human genes 0.000 claims description 3
- 108060005986 Granzyme Proteins 0.000 claims description 3
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 claims description 3
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims description 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 3
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 3
- 108010091175 Matriptase Proteins 0.000 claims description 3
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 3
- 108090000265 Meprin A Proteins 0.000 claims description 3
- 102100030876 Meprin A subunit beta Human genes 0.000 claims description 3
- 108090000263 Meprin B Proteins 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims description 3
- 108090000190 Thrombin Proteins 0.000 claims description 3
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- 229960004072 thrombin Drugs 0.000 claims description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000051957 human ERBB2 Human genes 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 108090000624 Cathepsin L Proteins 0.000 claims 1
- 102000004172 Cathepsin L Human genes 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063066565P | 2020-08-17 | 2020-08-17 | |
| US63/066,565 | 2020-08-17 | ||
| PCT/US2021/046217 WO2022040128A2 (en) | 2020-08-17 | 2021-08-17 | Constrained conditionally activated binding proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023538366A JP2023538366A (ja) | 2023-09-07 |
| JPWO2022040128A5 true JPWO2022040128A5 (enExample) | 2024-08-22 |
Family
ID=77655705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023511947A Pending JP2023538366A (ja) | 2020-08-17 | 2021-08-17 | 制約され、条件付きで活性化された結合タンパク質 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240026011A1 (enExample) |
| EP (1) | EP4196503A2 (enExample) |
| JP (1) | JP2023538366A (enExample) |
| KR (1) | KR20230048146A (enExample) |
| CN (1) | CN116419925A (enExample) |
| AR (1) | AR123266A1 (enExample) |
| AU (1) | AU2021329290A1 (enExample) |
| CA (1) | CA3191431A1 (enExample) |
| CL (1) | CL2023000477A1 (enExample) |
| CO (1) | CO2023002164A2 (enExample) |
| EC (1) | ECSP23018458A (enExample) |
| IL (1) | IL300598A (enExample) |
| MX (1) | MX2023002002A (enExample) |
| PE (1) | PE20230856A1 (enExample) |
| TW (1) | TW202214707A (enExample) |
| WO (1) | WO2022040128A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| MX2020002667A (es) | 2017-09-08 | 2020-08-03 | Maverick Therapeutics Inc | Proteinas de unión condicionalmente activadas restringidas. |
| TW202342521A (zh) * | 2022-02-23 | 2023-11-01 | 日商武田藥品工業股份有限公司 | 條件性雙特異性結合蛋白 |
| WO2024040220A2 (en) * | 2022-08-19 | 2024-02-22 | Regents Of The University Of Minnesota | Cd83 binding fusion proteins |
| WO2024040228A2 (en) * | 2022-08-19 | 2024-02-22 | Regents Of The University Of Minnesota | Cd83 binding proteins |
| WO2024147897A2 (en) * | 2023-01-05 | 2024-07-11 | Harpoon Therapeutics, Inc. | Trop2 targeting trispecific protein for treatment of cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20141522A1 (es) | 2011-08-17 | 2014-11-17 | Glaxo Group Ltd | Proteinas y peptidos modificados |
| TW201808990A (zh) | 2016-03-08 | 2018-03-16 | 馬弗瑞克療法公司 | 可誘導性結合蛋白和使用方法 |
| MX2020002667A (es) | 2017-09-08 | 2020-08-03 | Maverick Therapeutics Inc | Proteinas de unión condicionalmente activadas restringidas. |
| CN120484127A (zh) | 2019-03-05 | 2025-08-15 | 武田药品工业有限公司 | 受约束的条件性活化的结合蛋白 |
-
2021
- 2021-08-17 CA CA3191431A patent/CA3191431A1/en active Pending
- 2021-08-17 KR KR1020237009028A patent/KR20230048146A/ko not_active Withdrawn
- 2021-08-17 PE PE2023000289A patent/PE20230856A1/es unknown
- 2021-08-17 WO PCT/US2021/046217 patent/WO2022040128A2/en not_active Ceased
- 2021-08-17 MX MX2023002002A patent/MX2023002002A/es unknown
- 2021-08-17 TW TW110130298A patent/TW202214707A/zh unknown
- 2021-08-17 JP JP2023511947A patent/JP2023538366A/ja active Pending
- 2021-08-17 EP EP21766347.5A patent/EP4196503A2/en active Pending
- 2021-08-17 IL IL300598A patent/IL300598A/en unknown
- 2021-08-17 CN CN202180066644.9A patent/CN116419925A/zh active Pending
- 2021-08-17 US US18/021,730 patent/US20240026011A1/en active Pending
- 2021-08-17 AU AU2021329290A patent/AU2021329290A1/en not_active Abandoned
- 2021-08-17 AR ARP210102304A patent/AR123266A1/es not_active Application Discontinuation
-
2023
- 2023-02-16 CL CL2023000477A patent/CL2023000477A1/es unknown
- 2023-02-27 CO CONC2023/0002164A patent/CO2023002164A2/es unknown
- 2023-03-16 EC ECSENADI202318458A patent/ECSP23018458A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI812637B (zh) | 限制性條件性活化之結合蛋白 | |
| KR100484084B1 (ko) | 키메라성 폴리펩타이드, 이의 제조 방법 및 용도 | |
| CN107922486B (zh) | 异源二聚体多特异性抗体形式 | |
| JP2022065174A5 (enExample) | ||
| AU2018280683B2 (en) | Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA | |
| WO2021244089A1 (zh) | 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用 | |
| CN114390938B (zh) | 受约束的条件性活化的结合蛋白 | |
| JP2019513014A5 (enExample) | ||
| JPWO2019234220A5 (enExample) | ||
| GB2518221A (en) | Tetravalent antigen-binding protein molecule | |
| CN116419925A (zh) | 受限的条件激活的结合蛋白 | |
| CN105229036A (zh) | 在疏水性相互作用位点内引入了静电相互作用的蛋白及其制备方法 | |
| CN116745316A (zh) | 具有人血清白蛋白结构域的受限条件激活结合蛋白构建体 | |
| JP2025527303A (ja) | Ｉｌ－１８融合タンパク質およびｉｌ－１８を産生する方法 | |
| JP2003511078A (ja) | 複数のエピトープと融合した組換えタンパク質の精製 | |
| JPWO2022040128A5 (enExample) | ||
| US20230340159A1 (en) | Constrained conditionally activated binding proteins | |
| JPWO2020181140A5 (enExample) | ||
| JPWO2020181145A5 (enExample) | ||
| KR20250166225A (ko) | 표피 성장 인자 수용체를 표적화하는 조성물 및 이의 제조 방법 및 사용 방법 | |
| JP2009536821A5 (enExample) | ||
| CN117417456A (zh) | 一种多价Fab结合肽及其制备和应用 | |
| JP2023057069A5 (enExample) | ||
| AU2022237943A1 (en) | Hybrid molecule comprising an antibody fc fragment and at least one fibrin-derived citrullinated peptide, and uses thereof | |
| HK40032913A (en) | Constrained conditionally activated binding proteins |